Reply to Solari et al

Clinical Infectious Diseases

Volumn 59, Issue 2, 2014, Pages 319-320

  Moore, Thomas A ^a   Rodriguez, Andres ^b   Bakken, Johan S ^c  

^a Infectious Disease Consultants   (United States)

^b Infectious Diseases Society of America Emerging Infections Network   (United States)

^c St Luke's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTAMINATION; ENDOSCOPY; FATALITY; FECES; FECES MICROFLORA; HUMAN; INVASIVE PROCEDURE; LETTER; NASOGASTRIC TUBE; NOROVIRUS; PERITONEAL CAVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECIPIENT; VIRUS TRANSMISSION; BIOLOGICAL THERAPY; DRUG APPROVAL; GASTROINTESTINAL DISEASES; MICROBIOLOGY; PROCEDURES;

NEW DRUG;

BIOLOGICAL THERAPY; DRUGS, INVESTIGATIONAL; FECES; GASTROINTESTINAL DISEASES; HUMANS; INVESTIGATIONAL NEW DRUG APPLICATION;

EID: 84903935041     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu279     Document Type: Letter

References (3)

1. Solari PR, Fairchild PG, Noa LJ, Wallace MR. Tempered enthusiasm for fecal transplant. Clin Infect Dis. 2014; 10.1093/cid/ciu278.
2. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9:1044-9.
3. Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013; 108:1367.